The risk of certain birth defects is higher in women given opioid analgesics such as hydrocodone during pregnancy, according to a new study.
The risk of certain birth defects is higher in women given opioid analgesics such as hydrocodone during pregnancy, according to a new study.
Researchers with the Centers for Disease Control and Prevention (CDC) found that women who took codeine, hydrocodone, and other opioids just before pregnancy or in their first trimester were twice as likely to have babies with a serious heart defect. The study, published in a recent issue of the American Journal of Obstetrics and Gynecology, was based on data from the National Birth Defects Prevention Study.
Treatment with opioid analgesics was linked to spina bifida, hydrocephaly, glaucoma, gastroschisis, and congenital heart defects. Codeine and hydrocodone were used most frequently, representing 69% of the opioid analgesics used. The women were taking the medications for surgical procedures, chronic diseases, infections, and injuries.
Congenital heart defects are among the most common birth defects, affecting nearly 1% of US births, and are the main contributor to infant death attributable to birth defects, according to the CDC’s National Center on Birth Defects and Developmental Disabilities.
Links between the use of opioid analgesics and the occurrence of hydrocephaly, glaucoma, or gastroschisis have not been observed in previous studies and deserve further investigation.
"It's really important that women talk with their doctors, and talk about the potential benefits for these medications, as well as the potential risk for heart defects,” said Cheryl Broussard, the CDC epidemiologist who led the study.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More